AR056871A1 - Compuestos de pirimidina amida como inhibidores de pgds - Google Patents
Compuestos de pirimidina amida como inhibidores de pgdsInfo
- Publication number
- AR056871A1 AR056871A1 ARP060104348A ARP060104348A AR056871A1 AR 056871 A1 AR056871 A1 AR 056871A1 AR P060104348 A ARP060104348 A AR P060104348A AR P060104348 A ARP060104348 A AR P060104348A AR 056871 A1 AR056871 A1 AR 056871A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkoxy
- alkyl
- y1y2n
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos son utiles para tratar trastornos alérgicos y/o inflamatorios, particularmente trastornos tales como rinitis alérgica, asma y/o enfermedad pulmonar obstructiva cronica (COPD). Reivindicacion 1: Un compuesto de formula (1), en la que R1 es arilo, heteroarilo o cicloalquilo C5-6, estando cada uno de ellos opcionalmente sustituido con halo, alquilo C1-6, hidroxi, alcoxi C1-6, haloalquilo C1-4 o haloalcoxi C1-4; R2 es hidrogeno o alquilo C1-4; R3 es -P(=O)-(alcoxi)2 o Y1Y2N-SO2- , cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterociclilo, heterociclenilo, o alcarilo multicíclico, estando cada uno de ellos opcionalmente sustituido con acilo, ciano, nitro, halo, hidroxi, carboxi, amidino, R5O-C(=O)-C(=N-OR4)-, Y1Y2N-, Y1Y2N-C(=O)-, Y1Y2N-C(=O)-O-, Y1Y2N-SO2-, R7-SO2-NR6-, R7-C(=O)-NR6-, Y1Y2N-alquileno C1-4-SO2-alquileno C1-4-, o alquilo, alquenilo, alquinilo, alcoxi, alcoxicarbonilo, alquiltio, alquiIsulfinilo o alquilsulfonilo, estando cada uno de ellos opcionalmente sustituido con halo, alcoxi, haloalcoxi, hidroxi, carboxi, alcoxicarbonilo, -P(=O)-(alcoxi)2, Y1Y2N-, Y1Y2N-SO2-, R7-SO2-NR6-, arilo o heteroarilo, estando cada uno de ellos opcionalmente sustituido con alquilo, halo, haloalquilo, alcoxi, haloalcoxi, hidroxi, amino, alquilamino, dialquilamino, carboxi o alcoxicarbonilo, o heterociclilo o arilheterociclilo, estando cada uno de ellos opcionalmente sustituido con oxo o alquilo, o arilo, heteroarilo, aroílo, heteroaroílo, ariloxi, heteroariloxi o heterociclilo, estando cada uno de ellos opcionalmente sustituido con alquilo, haloalquilo, halo, alcoxi, haloalcoxi, hidroxi, carboxi, alcoxicarbonilo, -P(=O)-(alcoxi)2, Y1Y2N- o Y1Y2N-SO2-, y cuando R3 es cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo o alcarilo multicíclico, también está opcionalmente sustituido con oxo; L1 es un enlace o alquileno C1-6 opcionalmente sustituido con hidroxi, o cuando R3 es cicloalquilo opcionalmente sustituido, cicloalquenilo, arilo, heteroarilo, heterociclilo, heterociclenilo o alcarilo multicíclico, entonces el grupo alquileno C1-6 también está opcionalmente sustituido con -P(=O)-(alcoxi)2; cada uno de R4, R5 y R6 es independientemente hidrogeno o alquilo, R7 es alquilo opcionalmente sustituido con hidroxi, halo o alcoxi, o arilo, heteroarilo, arilalquilo o heteroarilalquilo, donde el grupo arilo o heteroarilo o el resto arilo o heteroarilo del grupo arilalquilo o heteroarilalquilo está opcionalmente sustituido con alquilo, haloalquilo, hidroxi, carboxi, alcoxicarbonilo, amino, alquilamino, dialquilamino, halo, alcoxi o haloalcoxi; y cada uno de Y1 e Y2 es independientemente hidrogeno, alquilo opcionalmente sustituido con hidroxi, carboxi, halo, amino, alquilamino, dialquilamino, cicloalquilamino, aminocarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo, cicloalquilaminocarbonilo, alcoxi opcionalmente sustituido con hidroxi, cicloalquilo, heterociclilo, arilo o heteroarilo, estando cada uno de ellos opcionalmente sustituido con alquilo, halo o haloalquilo, o cicloalquilo opcionalmente sustituido con carboxi, o Y1 e Y2 junto con el átomo de nitrogeno al que están unidos forman un heterociclilo que contiene opcionalmente otro heteroátomo seleccionado entre oxígeno, nitrogeno o azufre, donde el grupo heterociclilo está opcionalmente sustituido con alquilo u oxo; o un hidrato, solvato o N-oxido del mismo, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72357005P | 2005-10-04 | 2005-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056871A1 true AR056871A1 (es) | 2007-10-31 |
Family
ID=37635758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104348A AR056871A1 (es) | 2005-10-04 | 2006-10-03 | Compuestos de pirimidina amida como inhibidores de pgds |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8202863B2 (es) |
| EP (1) | EP1937652B1 (es) |
| JP (1) | JP5452925B2 (es) |
| KR (1) | KR101457966B1 (es) |
| CN (2) | CN101538246B (es) |
| AR (1) | AR056871A1 (es) |
| AU (1) | AU2006299428B2 (es) |
| BR (1) | BRPI0616815A2 (es) |
| CA (1) | CA2624749C (es) |
| CR (1) | CR9832A (es) |
| DO (1) | DOP2006000210A (es) |
| EC (1) | ECSP088335A (es) |
| ES (1) | ES2514471T3 (es) |
| IL (1) | IL190411A (es) |
| MA (1) | MA29925B1 (es) |
| MY (1) | MY151172A (es) |
| NO (1) | NO20082000L (es) |
| NZ (1) | NZ567208A (es) |
| PE (2) | PE20110118A1 (es) |
| RU (1) | RU2420519C2 (es) |
| SG (1) | SG166121A1 (es) |
| TN (1) | TNSN08104A1 (es) |
| TW (1) | TWI415839B (es) |
| UA (1) | UA93213C2 (es) |
| UY (1) | UY29840A1 (es) |
| WO (1) | WO2007041634A1 (es) |
| ZA (1) | ZA200802222B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200802411B (en) * | 2005-09-15 | 2009-09-30 | Orchid Res Lab Ltd | Novel pyrimidine carboxamides |
| PE20110118A1 (es) | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
| WO2008075172A2 (en) | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN104072489B (zh) * | 2007-08-27 | 2017-07-07 | 达特神经科学(开曼)有限公司 | 治疗用异噁唑化合物 |
| US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| US8389734B2 (en) | 2007-10-11 | 2013-03-05 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| MX2010003865A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| JP2011503072A (ja) * | 2007-11-13 | 2011-01-27 | レノビス， インコーポレイテッド | イオンチャネルのリガンドとしてのアミド誘導体ならびにそれを使用する薬学的組成物および方法 |
| CA2711399C (en) * | 2008-02-06 | 2016-10-11 | Banyu Pharmaceutical Co., Ltd. | 3-substituted sulfonylpiperidine derivative |
| EP2286221A4 (en) * | 2008-05-13 | 2011-07-06 | Cayman Chem Co | METHOD FOR TESTING COMPOUNDS OR MEANS FOR THEIR POSSIBILITY TO DISPLACE STRONG LIGANDS OF THE HEMATOPOIETIC PROSTAGLANDIN D-SYNTHASE |
| WO2009153720A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| PE20110843A1 (es) | 2008-09-22 | 2011-12-08 | Cayman Chem Co | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica |
| KR101252335B1 (ko) | 2009-07-16 | 2013-04-08 | (주)아모레퍼시픽 | 피부 노화 방지용 조성물 |
| KR101367057B1 (ko) | 2009-03-17 | 2014-02-25 | (주)아모레퍼시픽 | 피부 자극 완화용 조성물 |
| WO2010056044A2 (ko) * | 2008-11-11 | 2010-05-20 | (주)아모레퍼시픽 | 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 |
| JP5111657B2 (ja) | 2009-03-09 | 2013-01-09 | 大鵬薬品工業株式会社 | プロスタグランジンｄ合成酵素を阻害するピペラジン化合物 |
| BR112012007635B1 (pt) * | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
| CN102712626B (zh) | 2010-01-22 | 2014-09-17 | 大鹏药品工业株式会社 | 具有pgds抑制作用的哌嗪化合物 |
| US9320723B2 (en) * | 2010-05-03 | 2016-04-26 | University Of Rochester | Methods of treating thyroid eye disease |
| WO2011150457A2 (en) * | 2010-06-01 | 2011-12-08 | The University Of Queensland | Haematopoietic-prostaglandin d2 synthase inhibitors |
| AU2011299904A1 (en) | 2010-09-07 | 2013-05-02 | Taiho Pharmaceutical Co., Ltd. | Prostaglandin D synthase inhibitory piperidine compounds |
| KR101271223B1 (ko) | 2011-01-27 | 2013-06-07 | 한국과학기술연구원 | 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제 |
| BR112014016804A8 (pt) | 2012-01-06 | 2017-07-04 | Univ California | composições, métodos de uso e métodos de tratamento |
| ES2640049T3 (es) * | 2012-08-24 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Derivados de 3,6-dihidropirimidina 2,4,5,6-sustituidos como inhibidores de la polimerasa del virus de la hepatitis B (VHB) para el tratamiento de, por ejemplo, la hepatitis crónica |
| RU2018126105A (ru) | 2015-12-17 | 2020-01-17 | Астекс Терапьютикс Лимитед | Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds |
| US10669270B2 (en) * | 2016-03-14 | 2020-06-02 | Emory University | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| BR112019026452A2 (pt) | 2017-06-13 | 2020-07-14 | Glaxosmithkline Intellectual Property Development Limited | compostos químicos como inibidores de h-pgds |
| EP3700521B1 (en) * | 2017-10-29 | 2024-06-12 | China Medical University | Use of adam9 inhibitor compound and composition including adam9 inhibitor compound |
| WO2019116256A1 (en) | 2017-12-13 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Fused pyridines which act as inhibitors of h-pgds |
| WO2019179652A1 (en) * | 2018-03-23 | 2019-09-26 | Step Pharma S.A.S. | Aminopyrimidine derivatives as ctps1 inhibitors |
| EP3877384A1 (en) | 2018-11-08 | 2021-09-15 | GlaxoSmithKline Intellectual Property Development Ltd | Chemical compounds |
| CN116997548A (zh) * | 2020-05-13 | 2023-11-03 | Chdi基金会股份有限公司 | 用于治疗亨廷顿病的htt调节剂 |
| JPWO2021256569A1 (es) | 2020-06-19 | 2021-12-23 | ||
| EP4232425A4 (en) * | 2020-10-23 | 2024-07-24 | Nimbus Clotho Inc | CTPS1 INHIBITORS AND USES THEREOF |
| CN113004208A (zh) * | 2021-03-08 | 2021-06-22 | 沈阳药科大学 | 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用 |
| EP4433471A1 (en) * | 2021-11-17 | 2024-09-25 | CHDI Foundation, Inc. | N-(2h-indazol-5-yl)pyrazine-2-carboxamide derivatives and similar compounds as htt modulators for the treatment of huntington's disease |
| JPWO2023113023A1 (es) | 2021-12-17 | 2023-06-22 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| JP2000226372A (ja) * | 1999-02-01 | 2000-08-15 | Nippon Soda Co Ltd | アミド化合物、その製造方法及び農園芸用殺虫剤 |
| WO2001021577A2 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| JP2003112985A (ja) | 2001-10-01 | 2003-04-18 | Nre Happiness Kk | 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット |
| AU2003248122A1 (en) * | 2002-07-25 | 2004-02-16 | Kotobuki Pharmaceutical Co., Ltd. | Sodium channel inhibitor |
| CA2494102A1 (en) * | 2002-07-30 | 2004-02-05 | Banyu Pharmaceutical Co., Ltd. | Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| ATE450533T1 (de) * | 2003-02-14 | 2009-12-15 | Glaxo Group Ltd | Carboxamidderivate |
| DE60303238T2 (de) * | 2003-04-25 | 2006-09-14 | Actimis Pharmaceuticals, Inc., La Jolla | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
| WO2005032493A2 (en) | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| US20050165028A1 (en) * | 2004-01-23 | 2005-07-28 | Norman Mark H. | Vanilloid receptor ligands and their use in treatments |
| PE20110118A1 (es) | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
-
2006
- 2006-10-03 PE PE2010000532A patent/PE20110118A1/es not_active Application Discontinuation
- 2006-10-03 PE PE2006001202A patent/PE20070589A1/es not_active Application Discontinuation
- 2006-10-03 DO DO2006000210A patent/DOP2006000210A/es unknown
- 2006-10-03 AR ARP060104348A patent/AR056871A1/es unknown
- 2006-10-04 UY UY29840A patent/UY29840A1/es unknown
- 2006-10-04 RU RU2008117170/04A patent/RU2420519C2/ru not_active IP Right Cessation
- 2006-10-04 EP EP06816247.8A patent/EP1937652B1/en active Active
- 2006-10-04 WO PCT/US2006/038841 patent/WO2007041634A1/en active Application Filing
- 2006-10-04 AU AU2006299428A patent/AU2006299428B2/en not_active Ceased
- 2006-10-04 SG SG201007241-1A patent/SG166121A1/en unknown
- 2006-10-04 UA UAA200805322A patent/UA93213C2/ru unknown
- 2006-10-04 JP JP2008534664A patent/JP5452925B2/ja active Active
- 2006-10-04 NZ NZ567208A patent/NZ567208A/en not_active IP Right Cessation
- 2006-10-04 BR BRPI0616815-9A patent/BRPI0616815A2/pt not_active IP Right Cessation
- 2006-10-04 ES ES06816247.8T patent/ES2514471T3/es active Active
- 2006-10-04 KR KR1020087008306A patent/KR101457966B1/ko not_active IP Right Cessation
- 2006-10-04 CA CA2624749A patent/CA2624749C/en not_active Expired - Fee Related
- 2006-10-04 CN CN200910138053.9A patent/CN101538246B/zh active Active
- 2006-10-04 TW TW095136806A patent/TWI415839B/zh not_active IP Right Cessation
- 2006-10-04 MY MYPI20080754 patent/MY151172A/en unknown
- 2006-10-04 CN CNA2006800365786A patent/CN101282943A/zh active Pending
-
2008
- 2008-03-07 TN TNP2008000104A patent/TNSN08104A1/en unknown
- 2008-03-10 ZA ZA200802222A patent/ZA200802222B/xx unknown
- 2008-03-24 IL IL190411A patent/IL190411A/en not_active IP Right Cessation
- 2008-03-26 CR CR9832A patent/CR9832A/es not_active Application Discontinuation
- 2008-04-02 EC EC2008008335A patent/ECSP088335A/es unknown
- 2008-04-04 US US12/062,641 patent/US8202863B2/en active Active
- 2008-04-28 NO NO20082000A patent/NO20082000L/no not_active Application Discontinuation
- 2008-05-02 MA MA30891A patent/MA29925B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056871A1 (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| AR065874A1 (es) | Compuestos de pirimidina hidrazida como inhibidores de pgds | |
| PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
| ES2430139T3 (es) | Compuestos de piperidina 3,5-sustituido como inhibidores de renina | |
| AR106744A2 (es) | Formas cristalinas de un compuesto de bifenilo | |
| ES2880151T3 (es) | Derivados de pirano como inhibidores de CYP11A1 (citocromo P450 monooxigenasa 11A1) | |
| PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| NO20091012L (no) | Kinazolinon- og isokinolinonacetamid derivater | |
| PE20060373A1 (es) | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| PE20130774A1 (es) | Compuestos heterociclicos activadores de ampk y metodos para emplearlos | |
| AR071609A1 (es) | Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1 | |
| TW200611907A (en) | Fused heterocyclic compound | |
| PE20130188A1 (es) | Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk | |
| CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
| NO20092415L (no) | Heteromonocyklisk forbindelse og anvendelse derav | |
| MY155653A (en) | Triazine compounds as p13 kinase and mtor inhibitors | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| BRPI0519597A2 (pt) | derivados de (3r, 6r)-3-(2, 3-diidro-1h-inden-2-il)-2, 5-piperazinadiona 1, 6-substituÍda como antagonistas de receptores de oxitocina para o tratamento de parto prematuro, dismenorrÉia e endometriose | |
| EA201591239A1 (ru) | Замещенные фталазин-1(2h)-оновые производные в качестве селективных ингибиторов поли(адф-рибоза)полимеразы-1 | |
| PE20080139A1 (es) | Compuestos de pirrolotriazina anilina como inhibidores de cinasa | |
| ES2653419T3 (es) | Pirazolopirimidinilamino-indazoles sustituidos | |
| AR076798A1 (es) | Pirazinilpirazoles y composiciones que comprenden dichos compuestos | |
| WO2005070884A3 (en) | Heterocyclic compounds useful as growth hormone secretagogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |